An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer
, Pawel Rajwa 1,3, Tatsushi Kawada 1,4, Kensuke Bekku 1,4, Ekaterina Laukhtina 1,5, Markus von Deimling 1,6, Muhammad Majdoub 1,7, Marcin Chlosta 1,8, Pierre I. Karakiewicz 9, Axel Heidenreich 1,10, Takahiro Kimura 2 and Shahrokh F. Shariat 1,5,11,12,13,14,15,*Round 1
Reviewer 1 Report
In this mini-review authors summarized the safety, oncologic, and functional outcomes of cytoreductive prostatectomy in metastatic prostate cancer. The results and conclusion are based on 27 studies that they find in three databases. Overall, cytoreductive prostatectomy shows oncologic benefits compared to radiotherapy or no local therapy for metastatic prostate cancer.
The review is well-written and easy to understand.
Authors should check for minor corrections: name of Table 1 (Table 1.) without dot, in line 160 space after 2015 (check for spaces like the previous example in the entire text), and improve the resolution of Figure 1.
Author Response
We thank the reviewer for the detailed check of our manuscript and helpful comments. Please see the attachment.
Author Response File: 
Author Response.docx
Reviewer 2 Report
This paper reviewed a series of publications on case studies as references for evaluating the effect of cytoreductive prostatectomy(cRP) on metastatic prostate cancer(mPCa) in a very detailed manner. There are a couple of small issues that needs to be addressed before publication.
1. Line 54-55: the authors might provide more details on the definition of low vs high-volume disease from the references. What is the rationale here on why all the therapies discussed below are all dealing with low-volume disease?
2. Line 217-220: It is clear that all the six case studies between cRP vs NLT have very small patient numbers compared to population based studies and the indication here is contradictory between studies. Just out of curiosity, can these small patient numbers from different dataset be combined together to get a better picture just like in population based studies? Maybe can discuss a little more here.
3. Line 269-272: It might be better to discuss a little bit more here on what is the indication for the huge range of Positive surgical margin (PSM) and PLND here. Does that indicate the effectiveness of cRP might be really variable between patients?
Author Response
We appreciate the reviewer's valuable comments and suggestions. Please see the attachment.
Author Response File: Author Response.docx
